Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Britannia Life Sciences Inc Com C.RLSC

RISE Life Science Corp is engaged in developing and evolving medical and adult hemp-based formulations to create general use of health and well-being products for the emerging consumer category. It derives key revenue from the United States.


CSE:RLSC - Post by User

Comment by lscfaon Apr 21, 2020 2:18pm
157 Views
Post# 30935226

RE:RE:RE:Closing conditions

RE:RE:RE:Closing conditions

Called it....

As a condition of the Transaction, all current debentures in RISE totaling C$5.365 million, upon closing of the Transaction, must be converted into common shares of RISE at a conversion price of C$0.075 per common share.

https://www.newsfilecorp.com/release/54701/RISE-Life-Science-Corp.-Announces-Revised-Private-Placement-Structure-Led-by-Canaccord-Genuity-Corp.?k=




lscfa wrote: Make that $0.07 conversion rate for convertible notes. o/s notes of ~ $5.8 mil / 82 mil shares = $0.07       



19.   Subsequent Events:

On December 6th, 2019, the Company announced that it would be returning the escrowed proceeds of its April 1, 2019 financing $2,050,000 (note 10(iv)) as the Company did not complete a qualifying CBD related investment.


 

lscfa wrote:

I think the co. is hoping to offer debenture holders a reduced conversion rate of $0.09 to entice them to convert.

scientus 500 million Shs / 67% => 746 million total shares

Rise shareholders 19% of 746 million = 142 million shs

debentue holders = 142 mil - 60 mil common shares = 82 mil

$7.5 mil debentures/ 82 mil shs = $0.09 conversion rate

The final structure of the Transaction will be determined by the parties following receipt of tax, corporate and securities law advice. The Transaction is an arm's length transaction. Upon the closing of the Transaction (the "Closing") it is expected that current shareholders of RISE (after the conversion of the outstanding RISE convertible debentures, discussed below) will hold approximately 19% of the Resulting Issuer Shares, existing shareholders of Scientus will hold approximately 67% of the Resulting Issuer Shares and the new shareholders as a result of the private placement financing (described below) will hold approximately 14% on a non-diluted basis.


 

lscfa wrote:

 

How is co going to get debenture holders to convert? Most of the debentures are convertible at $0.15. Probably need to do $10 million PP and use $7.5 mil to redeem debentures.




"Conversion of all outstanding RISE convertible debentures"

"Successful completion by Rise of a minimum $5 million private placement financing"


 




<< Previous
Bullboard Posts
Next >>